Atara Biotherapeutics Inc
NASDAQ:ATRA

Watchlist Manager
Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc
NASDAQ:ATRA
Watchlist
Price: 7.14 USD 0.42% Market Closed
Market Cap: 42.6m USD

Wall Street
Price Targets

ATRA Price Targets Summary
Atara Biotherapeutics Inc

Wall Street analysts forecast ATRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATRA is 15.64 USD with a low forecast of 11.11 USD and a high forecast of 18.9 USD.

Lowest
Price Target
11.11 USD
56% Upside
Average
Price Target
15.64 USD
119% Upside
Highest
Price Target
18.9 USD
165% Upside
Atara Biotherapeutics Inc Competitors:
Price Targets
LEGN
Legend Biotech Corp
171% Upside
2616
CStone Pharmaceuticals
27% Downside
002007
Hualan Biological Engineering Inc
22% Upside
002252
Shanghai RAAS Blood Products Co Ltd
2% Upside
2256
Abbisko Cayman Ltd
36% Upside
NTRA
Natera Inc
27% Upside
688428
InnoCare Pharma Ltd
14% Downside
BMRN
Biomarin Pharmaceutical Inc
69% Upside

Revenue
Forecast

Revenue Estimate
Atara Biotherapeutics Inc

The compound annual growth rate of Atara Biotherapeutics Inc's revenue for the next 3 years is -43%.

N/A
Past Growth
-43%
Estimated Growth
Estimates Accuracy
-41%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Atara Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Atara Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-54%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ATRA's stock price target?
Price Target
15.64 USD

According to Wall Street analysts, the average 1-year price target for ATRA is 15.64 USD with a low forecast of 11.11 USD and a high forecast of 18.9 USD.

What is Atara Biotherapeutics Inc's Revenue forecast?
Projected CAGR
-43%

The compound annual growth rate of Atara Biotherapeutics Inc's revenue for the next 3 years is -43%.

Back to Top